PIK3CA Breast Cancer

Focus Panel testing is also being funded by Novartis for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that has progressed after treatment with hormonal therapy in postmenopausal women and men

The goal of this testing is to identify mutations in the PIK3CA gene, that may allow these patients to qualify for targeted therapy with the PIK3CA inhibitor Alpelisib (Piqray®).